About this study
Some children and young people develop cancers that start in bones or soft tissues like muscles and together are known as sarcomas. These cancers are hard to cure if they come back after treatment (relapse) or do not respond to usual treatments (refractory).
The RAD3CAR trial is studying a new kind of therapy to see if it is safe and if it might help when other treatments have not worked.
This study combines short-course, high-dose radiation therapy with a special type of immunotherapy called CAR T–cell therapy. Immunotherapy is a treatment that helps your body's own defense system (immune system) fight cancer. CAR T–cell therapy uses some of the patient’s own cells to fight disease. These cells are removed and changed in a lab so they can find and attack a small marker on the cancer cells. This marker is called B7-H3.
Patients will first receive radiation therapy over several days. After that, they will get chemotherapy for 4 days. Chemotherapy helps make space in the body so the CAR T cells can grow and fight the cancer. Then the patient will receive the CAR T cells through an IV.
Doctors will watch patients closely for side effects and see how the cancer responds. Some patients will also have tumor biopsies before and after treatment. A biopsy is a small sample of tissue that helps doctors learn how the therapy affects cancer.
The main goal of this study is to see if this combined approach is safe. The study will also look at how well the therapy works against sarcomas and how the CAR T cells behave in the body. Learning how radiation and CAR T cells work together could lead to new ways to treat sarcomas that are hard to cure.
Eligibility overview
- Up to 21 years old
- Has a relapsed or refractory sarcoma that is positive for the B7-H3 marker
- Has at least 1 tumor lesion that can be treated with a short course of high-dose radiation